A Phase 1 interventional study of LY4405094 and LY4405094 in Alzheimer Disease, Amyloid and Plaque, Amyloid, sponsored by Eli Lilly and Company. Recruiting at 19 sites in 3 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Alzheimer Disease by Eli Lilly and Company — 13 open to participants now, 19 under way, 8 of them phase 3. Alzheimer Disease · Eli Lilly and Company.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 31st largest by planned enrollment of the 95 interventional ones that give a count, is one of 9 that started in 2026, is one of 34 in phase 1, reaches primary completion later than 9 of the 18 other live ones, and was the 96th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →13 of the 99 studies in Alzheimer Disease by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, China, Japan
Ages 18–85 · Healthy volunteers
Eli Lilly and Company · Sites in United States, China, Japan
Ages 18–85 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Japan, Puerto Rico
Ages 55+
Eli Lilly and Company · Sites in United States, Australia, New Zealand and 1 more country
Ages 50–85
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
By country, each count listing its studies:
Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 28 · Phase 3 27 · Phase 4 5
First in 2002; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 179 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 95 across the 95 interventional studies, 859 across the 4 observational. Of the 79 that completed or were terminated, 61 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
3 of the studies in Alzheimer Disease by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026866Phase 3Eli Lilly and CompanyA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | 2027-11 |
| NCT06657768Eli Lilly and CompanyA Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | 2027-07 |
| NCT07598370Eli Lilly and CompanyA Study of LY3439539 in Participants With Alzheimer's Disease | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).
Participants must meet eligibility criteria below. Additional criteria are specified in the substudy to which the participant will enroll.
Inclusion Criteria for Healthy Participants:
Inclusion Criteria for Participants with Alzheimer's Disease (AD):
Exclusion Criteria for all Participants:
Exclusion Criteria for Healthy Participants:
Exclusion Criteria for Participants with AD:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY4405094 or placebo administered intravenously (IV) or subcutaneously (SC) in healthy volunteers.
Drug: LY4405094 · Drug: Placebo
LY4405094 or placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan.
Drug: LY4405094 · Drug: Placebo · Other: Florbetapir F18 · Other: Florbetaben F 18
Administered intravenously (IV)
Administered Subcutaneously (SC)
Administered IV
Administered SC
Administered IV
Administered IV
The number of participants allocated to each substudy
Time frame: Baseline up to Day 160
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.
Of 162 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 22 months is above that.
Counting every sponsor, half of 235 studies reached it within 17 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.